About HUTCHMED DRC

HUTCHMED (HKEX:0013), (NASDAQ:HCM) is a global biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company is known for its robust pipeline of innovative drug candidates, several of which are in advanced stages of clinical trials with the aim of addressing unmet medical needs across various regions. HUTCHMED is committed to advancing healthcare by developing highly effective treatments, with a focus on bringing novel solutions to patients worldwide. The company actively collaborates with academic, industrial, and healthcare partners to expand its reach and impact in the healthcare sector.

Snapshot

Public USOwnership

2000Year founded

680Employees

Hong KongHead office

Loading Map...

Global footprint

Operations

All Locations

Products and/or services of HUTCHMED DRC

Oncology treatments focused on inhibiting cancer cell growth
Targeted therapies for solid tumors and hematologic malignancies
Research and development in tyrosine kinase inhibitors
Global partnerships for drug discovery and development
Manufacturing services for pharmaceutical products
Clinical trial management and execution services

HUTCHMED DRC executive team

Mr. Chig Fung Cheng BEc, CAActing CEO, CFO & Executive Director
Dr. Wei-Guo Su B.Sc., Ph.D.CEO, Chief Scientific Officer & Executive Director (Leave of Absence)
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.ECompany Secretary & Non-Executive Director
Ms. Yiling CuiExecutive VP & Head of Operations
David NgHead of Investor Relations & Capital Strategies
Mr. Charles George Rupert NixonGroup General Counsel
Mr. Kin Hung Lee M.B.A.Senior Vice President of Corporate Management & Communications
Ms. Selina ZhangSenior Vice President of Global Human Resources
Dr. Qingmei Wang Ph.D.Executive Vice President of Business Development & Strategic Alliances
Dr. Thomas FuSenior Vice President of Global Quality